| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -98,404 | -66,761 |
| Stock-based compensation expense | 12,498 | 8,190 |
| Right-of-use asset - operating lease | -860 | -568 |
| Amortization (accretion) of premium (discount) on investment securities | 2,655 | 1,891 |
| Other non-cash items | -165 | -88 |
| Accounts receivable | 17,243 | - |
| Prepaid expenses and other assets | 13,106 | 8,581 |
| Accounts payable | -3,184 | -3,582 |
| Accrued expenses | 3,054 | 2,480 |
| Operating lease liabilities | -893 | -587 |
| Deferred revenue | 16,537 | - |
| Net cash used in operating activities | -102,371 | -70,076 |
| Purchases of short-term investments | 1,409,582 | 1,339,835 |
| Sales and maturities of short-term investments | 1,549,000 | 1,427,000 |
| Purchases of property and equipment | 590 | 590 |
| Net cash provided by (used in) investing activities | 138,828 | 86,575 |
| Proceeds from exercise of stock options and warrants | 3 | - |
| Net cash provided by financing activities | 3 | - |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 36,460 | 16,499 |
| Cash and cash equivalents at beginning of period | 59,820 | - |
| Cash and cash equivalents at end of period | 96,280 | - |
Astria Therapeutics, Inc. (ATXS)
Astria Therapeutics, Inc. (ATXS)